Get the Stockscreener App
17.89
3.71%
0.64
Beam Therapeutics Inc stock is traded at $17.89, with a volume of 1.65M.
It is up +3.71% in the last 24 hours and up +7.64% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$17.25
Open:
$17.48
24h Volume:
1.65M
Relative Volume:
0.71
Market Cap:
$1.80B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-9.884
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+2.76%
1M Performance:
+7.64%
6M Performance:
-25.61%
1Y Performance:
-24.80%
1-Day Range:
$17.18
$17.96
1-Week Range:
$16.65
$19.15
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
17.89 | 1.75B | 352.57M | -143.01M | -153.40M | -1.81 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Mercer Global Advisors Inc. ADV Sells 4,568 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Tower Research Capital LLC TRC Sells 5,172 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics to Highlight New Data from BEAM-101 Program in - GuruFocus
Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference - Nasdaq
Beam Therapeutics to Highlight New Data from BEAM-101 - GlobeNewswire
New Clinical Data Reveals: BEAM-101 Treatment Progress in 17 Sickle Cell PatientsKey Findings Coming - Stock Titan
News: The Latest Clinical Trial Updates from CRISPR Medicine News - CRISPR Medicine News
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp - Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Stifel Financial Corp - Defense World
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Beam Therapeutics (BEAM) Gains FDA RMAT Designation for BEAM-302 - GuruFocus
Beam : FDA Grants RMAT Designation To BEAM-302 For Alpha-1 Antitrypsin Deficiency Treatment - Nasdaq
FDA grants RMAT status to Beam’s AATD gene therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - Stock Titan
HC Wainwright Issues Positive Forecast for BEAM Earnings - Defense World
FY2025 EPS Estimates for BEAM Cut by Cantor Fitzgerald - Defense World
(BEAM) Investment Report - news.stocktradersdaily.com
Wells Fargo & Company Cuts Beam Therapeutics (NASDAQ:BEAM) Price Target to $70.00 - Defense World
Guggenheim Cuts Beam Therapeutics (NASDAQ:BEAM) Price Target to $55.00 - Defense World
Q2 EPS Forecast for Beam Therapeutics Reduced by Analyst - Defense World
Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth? - Yahoo Finance
Guggenheim Lowers Price Target for Beam Therapeutics (BEAM) | BE - GuruFocus
Guggenheim Lowers Price Target for Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus
BEAM Stock: Wells Fargo Analyst Lowers Price Target to $70 | BEAM Stock News - GuruFocus
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates - The Globe and Mail
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) | BEA - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus
10 Analysts Assess Beam Therapeutics: What You Need To Know - Benzinga
Guggenheim Adjusts Price Target for Beam Therapeutics (BEAM) Amid Ongoing Developments | BEAM Stock News - GuruFocus
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim - TipRanks
Beam Therapeutics (BEAM) Target Price Cut by Wells Fargo Analyst | BEAM Stock News - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) to $2 - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) to $25 | BEAM Stock News - GuruFocus
Beam Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Why Beam Therapeutics (BEAM) Stock Plummeted Today - GuruFocus
Why Beam Therapeutics Stock Tanked on Tuesday - AOL.com
Why Beam Therapeutics Stock Tanked On Tuesday - Barchart.com
Beam Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$1.24 Mi - GuruFocus
Beam Therapeutics Shares Fall After Q1 Net Loss Widens - marketscreener.com
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Beam (BEAM) Reports Lower-than-Expected Q1 Revenue, Advances Cli - GuruFocus
Beam Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q1 License and Collaboration Revenue $7.5M - marketscreener.com
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q1 Loss $1.24, vs. FactSet Est of -$1.18 - marketscreener.com
Beam (BEAM) Reports Lower-than-Expected Q1 Revenue, Advances Clinical Programs | BEAM Stock News - GuruFocus
Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '25 |
Sale |
18.35 |
30,663 |
562,684 |
986,249 |
| Ciaramella Giuseppe | President |
Apr 01 '25 |
Sale |
18.35 |
7,434 |
136,418 |
190,216 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '25 |
Sale |
18.35 |
3,015 |
55,330 |
44,512 |
| Simon Amy | Chief Medical Officer |
Apr 02 '25 |
Sale |
17.73 |
20,997 |
372,294 |
65,742 |
| Simon Amy | Chief Medical Officer |
Apr 01 '25 |
Sale |
18.35 |
9,566 |
175,542 |
86,739 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):